About Us

Overview

AdvanDx develops and markets molecular-based, in vitro diagnostic tests that aid in the diagnosis and prevention of infectious diseases. The rapid test results are available in hours instead of days and allow healthcare providers to make more informed therapy decisions early and improve both the quality of patient care and overall hospital operations.

PNA FISH™ and EVIGENE™ tests provide rapid identification results for bacteria and yeast to support appropriate antibiotic therapy and improve overall patient care.  PNA FISH is available for in vitro diagnostic use (IVD) in the United States, Canada and Europe while EVIGENE is available for research use only (RUO) in the United States and for in vitro diagnostic use in Europe. (Please refer to the individual products for information on the regulatory status)

History

The company was founded in 2002 by Thais T. Johansen and Dr. Henrik Stender to capitalize on the unique properties of the PNA technology and its potential in diagnostics. The first products, PNA FISH for identification of bacteria and yeast directly from positive blood cultures, were launched in May 2003.

Headquartered on the 128 technology highway around Boston, AdvanDx has established R&D facilities both in the United States and Denmark with sales and marketing capabilities located throughout the United States and Europe.

View our News & Events page for more information on AdvanDx.